To the full analysis
Colgate-Palmolive stock: growth
CLColgate-Palmolive reported $20.38B in revenue for fiscal 2025, up 1.4% on the prior year, up 4.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
2.7%
per year from 2006 to 2025, per share 4%
Earnings (Annual rate)
2.4%
per year from 2006 to 2025, per share 3.8%
Free cash flow (Annual rate)
5.4%
per year from 2006 to 2025, per share 6.7%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 4.4% | 2.4% | 2.7% |
| Revenue per share | 5.6% | 3.6% | 4.0% |
| Earnings | −4.6% | 4.4% | 2.4% |
| Earnings per share | −3.5% | 5.6% | 3.8% |
| Free cash flow | 1.9% | 4.9% | 5.4% |
| Free cash flow per share | 3.1% | 6.0% | 6.7% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $12.24B | $1.35B | $1.35B |
| 2007 | $13.79B | $1.74B | $1.62B |
| 2008 | $15.33B | $1.96B | $1.62B |
| 2009 | $15.33B | $2.29B | $2.7B |
| 2010 | $15.56B | $2.2B | $2.66B |
| 2011 | $16.73B | $2.43B | $2.36B |
| 2012 | $17.09B | $2.47B | $2.63B |
| 2013 | $17.42B | $2.24B | $2.53B |
| 2014 | $17.28B | $2.18B | $2.54B |
| 2015 | $16.03B | $1.38B | $2.26B |
| 2016 | $15.2B | $2.44B | $2.55B |
| 2017 | $15.45B | $2.02B | $2.5B |
| 2018 | $15.54B | $2.4B | $2.62B |
| 2019 | $15.69B | $2.37B | $2.8B |
| 2020 | $16.47B | $2.7B | $3.31B |
| 2021 | $17.42B | $2.17B | $2.76B |
| 2022 | $17.97B | $1.79B | $1.86B |
| 2023 | $19.46B | $2.3B | $3.04B |
| 2024 | $20.1B | $2.89B | $3.55B |
| 2025 | $20.38B | $2.13B | $3.63B |
Revenue by segment
How Colgate-Palmolive Company makes its money and how that has shifted. Names are as the company reports them.
- Oral, Personal and Home Care77%
- Pet Nutrition23%
Figures as a table
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oral, Personal and Home Care | $12.93B | $13.16B | $13.16B | $13.17B | $13.59B | $14.11B | $14.25B | $15.17B | $15.62B | $15.77B | 77.4% |
| Pet Nutrition | $2.26B | $2.29B | $2.39B | $2.53B | $2.88B | $3.31B | $3.71B | $4.29B | $4.48B | $4.61B | 22.6% |
| Total revenue | $15.2B | $15.45B | $15.54B | $15.69B | $16.47B | $17.42B | $17.97B | $19.46B | $20.1B | $20.38B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 23 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.